This identifies c-KIT inhibition as a mechanism for reducing microglial activation and neuroinflammatory phenotypes in AD brains and suggests a multiple mechanism process by which TKIs may be promoting therapeutic benefit. This evidence concerns the gene KIT and Alzheimer disease.